Literature DB >> 26779651

Expression and clinical significance of SALL4 and β-catenin in colorectal cancer.

Liliang Hao1, Yan Zhao2, Zhen Wang3, Hongzhuan Yin1, Xin Zhang1, Tao He4, Shanshan Song1, Shaolong Sun1, Baosheng Wang1, Zhijie Li5, Qi Su6.   

Abstract

Previous studies on the expression of Sal-like 4 (SALL4), a zinc finger transcription factor, had conflicting results in colorectal cancer (CRC). The main aim of this study was to investigate the expression of SALL4 and its relationship with β-catenin in CRC. Immunohistochemistry was performed to examine the expression of SALL4 and β-catenin in a cohort of 149 patients with CRC, 12 with atypical hyperplasia, 25 with benign tumor and 38 with normal tissue. Expression patterns of SALL4 and β-catenin and correlation with clinicopathological features were investigated. The relationship between SALL4 and β-catenin was examined by immunofluorescence and co-immunoprecipitation using CRC cell lines, SW480, SW620, HCT116 and HT29. Immunohistochemical analysis revealed significantly lower expression of SALL4 in CRC (46.3 %) than atypical hyperplasia (68.0 %, p < 0.05) and normal tissue (78.9 %, p < 0.01). Well-differentiated CRC seemed to express more SALL4 (47.6 %) than moderately (45.8 %) and poorly-differentiated cancers (18.8 %) (p < 0.05). However, SALL4 expression positively correlated with lymph node metastasis and tumor-node-metastasis (TNM) and Dukes stages (all p < 0.05) suggesting a new mechanism involved in the function of SALL4 in CRC. β-catenin was expressed significantly higher in CRC (69.1 %) than normal tissue (21.1 %, p < 0.01), and positively correlated with CA19-9 level in serum (p < 0.05). SALL4 and β-catenin were positively correlated in CRC (Spearman correlation coefficient R = 0.536, p < 0.01). The group of co-expression of the two molecules showed advanced lymph node metastasis, TNM stage and Dukes stage (all p < 0.05). Double-labeling immunofluorescence and co-immunoprecipitation indicated that SALL4 and β-catenin co-localized in the nucleus and cytoplasm and interacted. Taken together, our results revealed that SALL4 and β-catenin were positively correlated in CRC. In CRC cells, SALL4 and β-catenin co-localized and interacted. The function of SALL4 in promoting lymph node metastasis and advanced clinical stage might partly be due to the interaction with β-catenin.

Entities:  

Keywords:  Co-localization; Colorectal cancer; Immunohistochemistry; Interaction; SALL4; β-Catenin

Mesh:

Substances:

Year:  2016        PMID: 26779651     DOI: 10.1007/s10735-016-9656-5

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  32 in total

1.  Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer.

Authors:  K Maruyama; A Ochiai; S Akimoto; S Nakamura; S Baba; Y Moriya; S Hirohashi
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

2.  IVIC syndrome is caused by a c.2607delA mutation in the SALL4 locus.

Authors:  Irene Paradisi; Sergio Arias
Journal:  Am J Med Genet A       Date:  2007-02-15       Impact factor: 2.802

3.  Overexpression of SALL4 in lung cancer and its importance in cell proliferation.

Authors:  Daisuke Kobayashi; Kageaki Kuribayashi; Maki Tanaka; Naoki Watanabe
Journal:  Oncol Rep       Date:  2011-07-01       Impact factor: 3.906

4.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

5.  Regulation of induced pluripotent stem (iPS) cell induction by Wnt/β-catenin signaling.

Authors:  Peilin Zhang; Wen-Hsuan Chang; Brendan Fong; Fan Gao; Chunming Liu; Denise Al Alam; Saverio Bellusci; Wange Lu
Journal:  J Biol Chem       Date:  2014-01-30       Impact factor: 5.157

6.  α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.

Authors:  Hiroko Ikeda; Yasunori Sato; Norihide Yoneda; Kenichi Harada; Motoko Sasaki; Seiko Kitamura; Yoshiko Sudo; Akishi Ooi; Yasuni Nakanuma
Journal:  Hum Pathol       Date:  2012-04-17       Impact factor: 3.466

7.  Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis.

Authors:  Libo Peng; Pin Tu; Xuan Wang; Shanshan Shi; Xiaojun Zhou; Jiandong Wang
Journal:  J Mol Histol       Date:  2014-06-05       Impact factor: 2.611

8.  Stemness factor Sall4 is required for DNA damage response in embryonic stem cells.

Authors:  Jianhua Xiong; Dilyana Todorova; Ning-Yuan Su; Jinchul Kim; Pei-Jen Lee; Zhouxin Shen; Steven P Briggs; Yang Xu
Journal:  J Cell Biol       Date:  2015-03-02       Impact factor: 10.539

9.  SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis.

Authors:  T Otsubo; Y Akiyama; K Yanagihara; Y Yuasa
Journal:  Br J Cancer       Date:  2008-02-12       Impact factor: 7.640

10.  Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database.

Authors:  Driss Ait Ouakrim; Cécile Pizot; Magali Boniol; Matteo Malvezzi; Mathieu Boniol; Eva Negri; Maria Bota; Mark A Jenkins; Harry Bleiberg; Philippe Autier
Journal:  BMJ       Date:  2015-10-06
View more
  11 in total

1.  Overexpression of insulin receptor substrate-4 is correlated with clinical staging in colorectal cancer patients.

Authors:  Patricia Sanmartín-Salinas; M Val Toledo-Lobo; Fernando Noguerales-Fraguas; María-Encarnación Fernández-Contreras; Luis G Guijarro
Journal:  J Mol Histol       Date:  2017-11-28       Impact factor: 2.611

2.  Smad4 and epithelial-mesenchymal transition proteins in colorectal carcinoma: an immunohistochemical study.

Authors:  M Ioannou; E Kouvaras; R Papamichali; M Samara; I Chiotoglou; G Koukoulis
Journal:  J Mol Histol       Date:  2018-02-21       Impact factor: 2.611

Review 3.  Functional and clinical significance of SALL4 in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik
Journal:  Tumour Biol       Date:  2016-07-21

4.  Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma.

Authors:  Jing He; Mingxia Zhou; Xinfeng Chen; Dongli Yue; Li Yang; Guohui Qin; Zhen Zhang; Qun Gao; Dan Wang; Chaoqi Zhang; Lan Huang; Liping Wang; Bin Zhang; Jane Yu; Yi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2016-06-21

5.  Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors.

Authors:  Jacinto García; Alberto Orfao; Luis Muñoz-Bellvís; José María Sayagués; María Laura Gutiérrez; Luis Antonio Corchete; María Eugenia Sarasquete; María Del Mar Abad; Oscar Bengoechea; Encarna Fermiñán; María Fernanda Anduaga; Sofía Del Carmen; Manuel Iglesias; Carmen Esteban; María Angoso; Jose Antonio Alcazar
Journal:  Oncotarget       Date:  2017-11-21

6.  Embryonic Stem Cell-Like Subpopulations in Venous Malformation.

Authors:  Elysia M S Tan; Sam Duro Siljee; Helen D Brasch; Susana Enriquez; Swee T Tan; Tinte Itinteang
Journal:  Front Med (Lausanne)       Date:  2017-10-04

7.  Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients.

Authors:  Zhuoyu Chen; Kaifei Li; Xiaofeng Yin; Haixia Li; Yao Li; Qiong Zhang; Haifang Wang; Yurong Qiu
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

Review 8.  SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.

Authors:  Boshu Sun; Liangliang Xu; Wenhui Bi; Wen-Bin Ou
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

Review 9.  SALL4: An Intriguing Therapeutic Target in Cancer Treatment.

Authors:  Shiva Moein; Daniel G Tenen; Giovanni Amabile; Li Chai
Journal:  Cells       Date:  2022-08-20       Impact factor: 7.666

Review 10.  SALL Proteins; Common and Antagonistic Roles in Cancer.

Authors:  Claudia Álvarez; Aracelly Quiroz; Diego Benítez-Riquelme; Elizabeth Riffo; Ariel F Castro; Roxana Pincheira
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.